Every 10-Q that GE HealthCare Technologies Inc. (GEHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GEHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GEHC filings page.
GE HealthCare Technologies Inc. reported Q2 2026 total revenues of $5,295 million, up from $5,007 million a year earlier, and first-half revenues of $10,425 million. Q2 net income attributable to GE HealthCare was $561 million (diluted EPS $1.24) versus $486 million ($1.06); first-half net income was $950 million ($2.08 diluted EPS) versus $1,049 million ($2.29).
Advanced Imaging Solutions generated Q2 revenues of $3,771 million, Pharmaceutical Diagnostics $843 million, and Patient Care Solutions $675 million. The company closed the $2,293 million cash acquisition of Intelerad, adding $1,629 million of goodwill and $845 million of definite-lived intangibles funded mainly with senior notes and a $650 million term loan.
Cash and equivalents fell to $2,108 million at June 30, 2026 from $4,515 million at the start of the year, reflecting acquisition spending and $300 million of share repurchases. Total borrowings were $10,093 million. GE HealthCare recognized $129 million of pre-tax tariff refund benefits and recorded $76 million in restructuring charges year-to-date.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.
GE HealthCare Technologies reported third‑quarter results reflecting steady growth. Total revenues were $5,143 million, up from $4,863 million a year ago, driven by higher product sales and services. Net income attributable to GE HealthCare was $446 million versus $470 million, and diluted EPS was $0.98 compared with $1.02. Operating income was $653 million, modestly below $676 million last year, as higher cost of products offset revenue gains.
For the first nine months, revenues reached $14,927 million and diluted EPS was $3.26. Cash from operating activities was $937 million. The company closed the acquisition of the remaining 50% of Nihon Medi‑Physics for $271 million cash consideration and recognized a $97 million remeasurement gain. It also issued $650 million 4.800% notes due 2031 and $850 million 5.500% notes due 2035. Cash and equivalents were $4,027 million, and total principal debt was $10,275 million. RPO was $15,096 million, indicating future revenue under contract. The company repurchased $200 million of stock year‑to‑date and declared dividends of $0.105 per share. Shares outstanding were 455,521,592 as of October 22, 2025.